This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cardlytics (CDLX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 54.55% and 19.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Jacobs Solutions (J) Q3 Earnings Beat Estimates
by Zacks Equity Research
Jacobs Solutions (J) delivered earnings and revenue surprises of 0.51% and 3.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 44.19% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Spotify (SPOT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Spotify (SPOT) delivered earnings and revenue surprises of -111.25% and 2.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Surges 13.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Cardlytics (CDLX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CleanSpark (CLSK) Soars 8.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CleanSpark (CLSK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Cardlytics (CDLX) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how Cardlytics (CDLX) and Trane Technologies (TT) have performed compared to their sector so far this year.
Does Cardlytics (CDLX) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 49.3% upside potential for Cardlytics (CDLX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cardlytics (CDLX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 37.50% and 4.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
Earnings Preview: NV5 Global (NVEE) Q1 Earnings Expected to Decline
by Zacks Equity Research
NV5 (NVEE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Cardlytics (CDLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardlytics (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardlytics (CDLX) Soars 80.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cardlytics (CDLX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Symbotic Inc. (SYM): Can Its 9.5% Jump Turn into More Strength?
by Zacks Equity Research
Symbotic Inc. (SYM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cardlytics (CDLX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 45.28% and 2.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cardlytics (CDLX): Can Its 12.1% Jump Turn into More Strength?
by Zacks Equity Research
Cardlytics (CDLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Cardlytics (CDLX) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Cardlytics (CDLX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
After Plunging 52% in 4 Weeks, Here's Why the Trend Might Reverse for Cardlytics (CDLX)
by Zacks Equity Research
Cardlytics (CDLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Cardlytics (CDLX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 7.41% and 2.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of -20.37% and 1.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 44.93% and 3.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Seagate (STX) Misses Q3 Earnings Estimates
by Zacks Equity Research
Seagate (STX) delivered earnings and revenue surprises of -3.21% and 0.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 63.41% and 16.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Copart, Inc. (CPRT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Copart, Inc. (CPRT) delivered earnings and revenue surprises of 5.77% and 10.24%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Soars 6.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cardlytics (CDLX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.